eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Eli Lilly and Company Limited

Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL
Telephone: +44 (0)1256 315 000
Fax: +44 (0)1256 775 858
WWW: http://www.lilly.co.uk
Medical Information e-mail: ukmedinfo@lilly.com
Medical Information Fax: +44 (0)1256 775 569

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 16/05/2012
SPC Humalog 100U/ml, solution for injection in vial, Humalog 100U/ml, solution for injection in Cartridge, Humalog KwikPen 100U/ml, solution for injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 16/05/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
  • Change to section 6. 3 - Shelf Life
Date of revision of text on the SPC:   13-Apr-2012
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company




 

Changes


6.             PHARMACEUTICAL PARTICULARS

 

6.3          Shelf-life

 

Unopened vials

2 years  3 years


10.          DATE OF REVISION OF THE TEXT

 

Revision date changed to:

 

 

13 April 2012

 

 

 

 

 

 

Updated on 13/05/2011 and displayed until 16/05/2012
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   18-Apr-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



PLEASE NOTE:  the SPC has been updated throughout in order to reflect QRD template changes and the removal of Humalog Pen information.

 

 

Changes

 

4.             CLINICAL PARTICULARS

 

4.8          Undesirable effects

 

Added (new) text:

 

Cases of oedema have been reported with insulin therapy, particularly if previous poor metabolic control is improved by intensified insulin therapy.

 

 

10.          DATE OF REVISION OF THE TEXT

 

Revision date changed to: 

 

18 April 2011

Updated on 07/03/2011 and displayed until 13/05/2011
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   17-Feb-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Added (new) text:

 

Changes

 

4.             CLINICAL PARTICULARS

 

4.4          Special warnings and precautions for use

 

Combination of Humalog with pioglitazone:

Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Humalog is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.

 

 

 

10.          DATE OF REVISION OF THE TEXT

 

Revision date changed to.

 

 

17 February 2011

 

 

 

OTHER CHANGE:

 

Individual affiliate contact details deleted from SPC consistent with other European SPCs.

 

Updated on 14/07/2009 and displayed until 07/03/2011
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 6 - Instructions for use, handling and disposal
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Jul-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



4.             CLINICAL PARTICULARS

4.5          Interaction with other medicinal products and other forms of interaction

 

Added (bold):

 

Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors),

 

 

 

6.             PHARMACEUTICAL PARTICULARS

 

6.3          Shelflife

 

Added:

 

Unopened vials

 

2 years

 

Unused cartridges and unused pre-filled pens

 

Added (bold) Deleted (strikethrough):

 

3 years 2 years

 

Added:

 

After cartridge insertion, or after first use (vial and prefilled pen)

 

Added (bold) deleted (strikethrough):

 

After cartridge insertion, or after first use (vial and prefilled pen) insertion of the cartridge in a pen, or the first use of the vial or prefilled pen, the solution should be used within 28 days. when stored below 30°C.

 

6.4          Special precautions for storage

 

Added:

 

Unused cartridge and unused pre-filled pens

 

Store in a refrigerator (2°C-8°C).  Do not freeze.  Do not expose to excessive heat or direct sunlight.

 

Added:

 

Unopened vials

Store in a refrigerator (2°C - 8°C).

 

After first use (vials only)

Store in a refrigerator (2°C - 8°C) or below 30°C.

 

After cartridge insertion or first use (pre-filled pen)

Store below 30°C. Do not refrigerate. The pen with the inserted cartridge and the pre-filled pen should not be stored with the needle attached.

 

6.6                Special precautions for disposal and other handling

 

Section re-formatted to provide better clarity between the pen and Kwikpen instructions.

 

 

 

9.             DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

 

Dates changed as per EMEA request:

 

Date of first authorisation:        30 April 1996

 

Date of last renewal:                   30 April 2006

 

 

 

10.          DATE OF REVISION OF THE TEXT

 

01 July 2009

Updated on 03/06/2008 and displayed until 14/07/2009
Reasons for adding or updating:
  • Introduction of new pack/pack size
Date of revision of text on the SPC:   31-Jan-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Addition:

 

This SPC has been revised in its entirety adding Humalog KwikPen text throughout – there are no other content changes and the date of revision of text remains the same.

 

10. DATE OF REVISION OF THE TEXT

 

31 January 2008

Updated on 06/03/2008 and displayed until 03/06/2008
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 6. 6 - Instructions for use, handling and disposal
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01/2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

4.       CLINICAL PARTICULARS

 

4.2          Posology and method of administration

 

 

Re-Formatted:

 

Use of HUMALOG in an insulin infusion pump:

Only certain CE-marked insulin infusion pumps may be used to infuse insulin lispro. Before infusing insulin lispro, the manufacturers instructions should be studied to ascertain the suitability or otherwise for the particular pump. Read and follow the instructions that accompany the infusion pump. Use the correct reservoir and catheter for the pump. Change the infusion set every 48 hours. Use aseptic technique when inserting the infusion set. In the event of a hypoglycaemic episode, the infusion should be stopped until the episode is resolved. If repeated or severe low blood glucose levels occur, notify your health care professional and consider the need to reduce or stop your insulin infusion. A pump malfunction or obstruction of the infusion set can result in a rapid rise in glucose levels. If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your health care professional. When used with an insulin infusion pump, HUMALOG should not be mixed with any other insulin.

 

Intravenous administration of insulin:

Intravenous injection of insulin lispro should be carried out following normal clinical practise for intravenous injections, for example by an intravenous bolus or by an infusion system. Frequent monitoring of the blood glucose levels is required.

Infusion systems at concentrations from 0.1U/ml to 1.0U/ml insulin lispro in 0.9% sodium chloride or 5% dextrose are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion to the patient.

 

 

 

6.             PHARMACEUTICAL PARTICULARS

 

6.6          Special precautions for disposal and other handling

 

 

Deleted from section 4.2 and inserted into section 6.6:

 

 

Instructions for Use and Handling

 

Humalog vials

 

The vial is to be used in conjunction with an appropriate syringe (100U markings).

 

a)            Preparing a dose

 

Inspect the Humalog solution.  It should be clear and colourless.  Do not use Humalog if it appears cloudy, thickened, or slightly coloured, or if solid particles are visible.

 

i)             Humalog

 

1.             Wash your hands.

 

2.             If using a new vial, flip off the plastic protective cap, but do not remove the stopper.

 

3.             If the therapeutic regimen requires the injection of basal insulin and Humalog at the same time, the two can be mixed in the syringe.  If mixing insulins, refer to the instructions for mixing that follow in section ii) and 6.2.

 

4.             Draw air into the syringe equal to the prescribed Humalog dose.  Wipe the top of the vial with an alcohol swab.  Put the needle through the rubber top of the Humalog vial and inject the air into the vial.

 

5.             Turn the vial and syringe upside down.  Hold the vial and syringe firmly in one hand.

 

6.             Making sure the tip of the needle is in the Humalog, withdraw the correct dose into the syringe.

 

7.             Before removing the needle from the vial, check the syringe for air bubbles that reduce the amount of Humalog in it.  If bubbles are present, hold the syringe straight up and tap its side until the bubbles float to the top.  Push them out with the plunger and withdraw the correct dose.

 

8.             Remove the needle from the vial and lay the syringe down so that the needle does not touch anything.

 

ii)            Mixing Humalog with longer-acting human insulins (see section 6.2)

 

1.                   Humalog should be mixed with longer-acting human insulins only on the advice of a doctor.

 

2.             Draw air into the syringe equal to the amount of longer-acting insulin being taken.  Insert the needle into the longer-acting insulin vial and inject the air.  Withdraw the needle.

 

3.             Now inject air into the Humalog vial in the same manner, but do not withdraw the needle.

 

4.             Turn the vial and syringe upside down.

 

5.             Making sure the tip of the needle is in the Humalog, withdraw the correct dose of Humalog into the syringe.

 

6.             Before removing the needle from the vial, check the syringe for air bubbles that reduce the amount of Humalog in it.  If bubbles are present, hold the syringe straight up and tap its side until the bubbles float to the top.  Push them out with the plunger and withdraw the correct dose.

 

7.             Remove the needle from the vial of Humalog and insert it into the vial of the longer-acting insulin.  Turn the vial and syringe upside down.  Hold the vial and syringe firmly in one hand and shake gently.  Making sure the tip of the needle is in the insulin, withdraw the dose of longer-acting insulin.

 

8.             Withdraw the needle and lay the syringe down so that the needle does not touch anything.

 

b)            Injecting a dose

 

1.                   Choose a site for injection.

 

2.             Clean the skin as instructed.

 

3.             Stabilise the skin by spreading it or pinching up a large area.  Insert the needle and inject as instructed.

 

4.             Pull the needle out and apply gentle pressure over the injection site for several seconds.  Do not rub the area.

 

5.             Dispose of the syringe and needle safely.

 

6.             Use of the injection sites should be rotated so that the same is not used more than approximately once a month.

 

c)             Mixing insulins

 

Do not mix insulin in vials with insulin in cartridges.  See section 6.2.

 

Humalog cartridges

 

Humalog cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.

 

a)            Preparing a dose

 

Inspect the Humalog solution.  It should be clear and colourless.  Do not use Humalog if it appears cloudy, thickened, or slightly coloured, or if solid particles are visible.

 

The following is a general description.  The manufacturer’s instructions with each individual pen must be followed for loading the cartridge, attaching the needle, and administering the insulin injection.

 

b)            Injecting a dose

 

1.             Wash your hands.

 

2.                   Choose a site for injection.

 

3.             Clean the skin as instructed.

 

4.             Remove outer needle cap.

 

5.             Stabilise the skin by spreading it or pinching up a large area.  Insert the needle as instructed.

 

6.             Press the knob.

 

7.             Pull the needle out and apply gentle pressure over the injection site for several seconds.  Do not rub the area.

 

8.             Using the outer needle cap, unscrew the needle and dispose of it safely.

 

9.                   Use of injection sites should be rotated so that the same site is not used more than approximately once a month.

 

c)             Mixing insulins

 

Do not mix insulin in vials with insulin in cartridges.  See section 6.2.

 

Humalog Pens

 

a)            Preparing a dose

 

1.             Inspect the Humalog Pen solution.

 

It should be clear and colourless.  Do not use Humalog Pen if it appears cloudy, thickened, or slightly coloured, or if solid particles are visible.

 

2.             Put on the needle.

 

Wipe the rubber seal with alcohol.  Remove the paper tab from the capped needle.  Screw the capped needle clockwise onto the pen until it is tight.  Hold the pen with needle pointing up and remove the outer needle cap and inner needle cover.

 

3.             Priming the pen (check insulin flow).

 

(a)           The arrow should be visible in the dose window.  If the arrow is not present, turn the dose knob clockwise until the arrow appears and notch is felt or visually aligned.

 

(b)           Pull dose knob out (in direction of the arrow) until a ‘0’ appears in the dose window.  A dose cannot be dialled until the dose knob is pulled out.

 

(c)           Turn dose knob clockwise until a ‘2’ appears in the dose window.

 

(d)           Hold the pen with needle pointing up and tap the clear cartridge holder gently with your finger so any air bubbles collect near the top.  Depress the injection button fully until you feel or hear a click.  You should see a drop of insulin at the tip of the needle.  If insulin does not appear, repeat the procedure until insulin appears.

 

(e)           Always prime the pen (check the insulin flow) before each injection.  Failure to prime the pen may result in an inaccurate dose.

 

4.             Setting the dose.

 

(a)           Turn the dose knob clockwise until the arrow appears in the dose window and a notch is felt or visually aligned.

 

(b)           Pull the dose knob out (in the direction of the arrow) until a ‘0’ appears in the dose window.  A dose cannot be dialled until the dose knob is pulled out.

 

(c)           Turn the dose knob clockwise until the dose appears in the dose window.  If too high a dose is dialled, turn the dose knob backward (anti-clockwise) until the correct dose appears in the window.  A dose greater than the number of units remaining in the cartridge cannot be dialled.

 

b)            Injecting a dose

 

1.             Wash your hands.

 

2.             Choose a site for injection.

 

3.             Clean the skin as instructed.

 

4.             Remove outer needle cap.

 

5.             Stabilise the skin by spreading it or pinching up a large area.  Insert the needle as instructed.

 

6.             Press the injection button down with the thumb (until you hear or feel a click); wait 5 seconds.

 

7.             Pull the needle out and apply gentle pressure over the injection site for several seconds.  Do not rub the area.

 

8.             Immediately after an injection, use the outer needle cap to unscrew the needle.  Remove the needle from the pen.  This will ensure sterility, and prevent leakage, re-entry of air, and potential needle clogs.  Do not reuse the needle.  Dispose of the needle in a responsible manner.  Needles and pens must not be shared.

 

The prefilled pen can be used until it is empty.  Please properly discard or recycle.

 

9.             Replace the cap on the pen.

 

10.          Use of injection sites should be rotated so that the same site is not used more than approximately once a month.

 

11.          The injection button should be fully depressed before using the pen again.

 

c)             Mixing insulins

 

Do not mix insulin in vials with insulin in cartridges.  See section 6.2.

 

 

 

 

 

10.          DATE OF REVISION OF THE TEXT

 

31 January 2008

Updated on 29/05/2007 and displayed until 06/03/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   05/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

4.             CLINICAL PARTICULARS

 

4.4          Special warnings and precautions for use

 

Added text in bold

 

Transferring a patient to another type or brand of insulin should be done under strict medical supervision.  Changes in strength, brand (manufacturer), type (soluble, isophane, lente, etc), species (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage.  For fast-acting insulins, any patient also on basal insulin must optimise dosage of both insulins to obtain glucose control across the whole day, particularly nocturnal/fasting glucose control.

 

4.5          Interaction with other medicinal products and other forms of interaction

 

Added text in bold

 

Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide, or alcohol.

 

 

 

5.             PHARMACOLOGICAL PROPERTIES

 

5.1          Pharmacodynamic properties

 

Deletions in strikethrough text

 

Clinical trials in patients with Type 1 and Type 2 diabetes have demonstrated reduced postprandial hyperglycaemia with insulin lispro compared to soluble human insulin.  For fast-acting insulins, any patient also on a basal insulin must optimise dosage of both insulins to obtain improved glucose control across the whole day.

 

 

 

10.          DATE OF REVISION OF THE TEXT

 

New date

 

3 May 2007

Updated on 26/09/2006 and displayed until 29/05/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 6. 6 - Instruction for Use/Handling
  • Change to section 8 - MA number
  • Change to section 9 - Date of Renewal of Authorisation
  • Change to section 10 (date of (partial) revision of the text
Date of revision of text on the SPC:   02/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

4.             CLINICAL PARTICULARS

 

4.2                Posology and method of administration

 

Text previously under the heading ‘Instructions for use, handling and disposal’ (section 6.6), now appears unchanged here.

 

4.8                Undesirable effects

 

Added:

 

No specific frequency for hypoglycaemia is presented, since hypoglycaemia is a result of both the insulin dose and other factors, eg, a patient’s level of diet and exercise.

 

Reworded:

 

Local allergy in patients is common (1/100 to <1/10).  Redness, swelling, and itching can occur at the site of insulin injection.  This condition usually resolves in a few days to a few weeks.  In some instances, this condition may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique.  Systemic allergy, which is rare (1/10,000 to <1/1,000) but potentially more serious, is a generalised allergy to insulin.  It may cause a rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating.  Severe cases of generalised allergy may be life-threatening.

 

Lipodystrophy at the injection site is uncommon (1/1,000 to <1/100).

 

6.             PHARMACEUTICAL PARTICULARS

 

6.5          Nature and contents of container

 

Added:

 

2 x 10ml Humalog vials.

5 x (1 x 10ml) Humalog vials.

 

2 x (5 x 3ml) Humalog cartridges for a 3ml pen.

 

2 x (5 x 3ml) Humalog Pens.

 

6.6          Special precautions for disposal

 

Added:

 

Any unused product or waste material should be disposed of in accordance with local requirements.

 

8.             MARKETING AUTHORISATION NUMBERS

 

Added:

 

Humalog vials

2 x 10ml Humalog vials:                   EU/1/96/007/020

5 x (1 x 10ml) Humalog vials:           EU/1/96/007/021


 

Humalog cartridges

2 x (5 x 3ml) Humalog cartridges for a 3ml pen:     EU/1/96/007/023

 

Humalog Pens

2 x (5 x 3ml) Humalog Pens:     EU/1/96/007/026

 

9.             DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

 

Date of first authorisation:                         Vial:                                30 April 1996

                                                                        3ml cartridge:                30 April 1996

                                                                        Humalog Pen 3ml:        30 April 1996

 

Date of renewal of the authorisation:       Vial:                                30 April 2006

                                                                        3ml cartridge:                30 April 2006

                                                                        Humalog Pen 3ml:        30 April 2006

 

10.          DATE OF REVISION OF THE TEXT

 

9 February 2006

Updated on 26/01/2004 and displayed until 26/09/2006
Reasons for adding or updating:
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 10 (date of (partial) revision of the text
Updated on 06/11/2003 and displayed until 26/01/2004
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 6.2 - Incompatibilities
  • Change to section 6. 6 - Instruction for Use/Handling
  • Change to section 10 (date of (partial) revision of the text
Updated on 17/06/2002 and displayed until 06/11/2003
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 6. 6 - Instruction for Use/Handling
  • Change to section 10 (date of (partial) revision of the text

Active Ingredients/Generics

 
   insulin lispro